Team

Back to team overview

Partner

Dr. Eva Ehlich

Partner

German Patent Attorney

European Patent Attorney

UPC Representative

Chemist

Eva represents European, US and Japanese companies in the chemical, biochemical and pharmaceutical sectors whom she advises and assists in drafting, prosecuting, defending, enforcing and challenging IP rights in Germany, Europe and worldwide. Along with preparing freedom-to-operate and validity analyses she has experience in patent litigation and strategic patent filing, SPCs, especially in the area of drug delivery, pharmaceutics and medical uses (small molecules and biologics including vaccines) as well as in coordinating international patent portfolios and freedom-to-operate strategies. In this context she coordinates as hub-counsel team-lead large attorney teams including attorneys from Maiwald and international partner law firms.

Eva has received numerous recognitions for her professional activities as a patent attorney.

since 2012
Partner, shareholder and managing director at Maiwald
since 2004
Patent attorney at Maiwald
2001 - 2004
Patent attorney trainee at Maiwald

2023
Admitted to practice before the UPC
2006
Passed the US patent agent examination
2005
Admitted to practice as European patent attorney
2004
Admitted to practice as German patent attorney
2001 - 2004
Studied law for patent attorneys at University of Hagen
1998 - 2001
Doctoral degree in the field of chemistry from the Technical University of Munich
1992 - 1998
Studied chemistry at the Technical University of Munich

  • Patent prosecution and portfolio management
  • Filing strategies and drafting patent applications
  • Freedom-to-operate and validity opinions
  • Opposition and nullity proceedings
  • Patent litigation

  • Recommended in Legal 500 Deutschland 2017, 2018, 2019, 2020, 2021, 2022, 2023, 2024
  • Listed in IAM Strategy 300 Global Leaders 2022, 2023, 2024
  • Recommended by IAM Strategy 300 as the World's leading IP Strategist 2021, 2022, 2023
  • Recommended in IAM Patent 1000 “World’s Leading Patent Professionals” 2020, 2021, 2022, 2023
  • Recommended in Handelsblatt | Best Lawyers "Germany's Best Lawyers" 2019, 2020, 2021, 2022, 2023
  • Listed as "Excellent" in the Leaders League Rankings Germany 2022 in the categorie Patent Prosecution
  • Recommended in MIP IP Stars 2017, 2018, 2019, 2020, 2021, 2022, 2023
  • "Highly recommended attorney" in JUVE Patent Rankings Germany 2021, 2022, 2023
  • Featured among Managing IP’s Top 250 Women in IP 2022
  • "Frequently recommended lawyer" in the JUVE Handbook of Commercial Law Firms 2017/ 2018, 2017/2018, 2018/2019, 2019/2020, 2020/2021, 2021/2022
  • Recommended in Legal 500 EMEA 2019, 2020, 2021, 2022

  • Opposition against EP 3 679 915 concerning a dengue vaccine (Opposition Division)
  • Appeal T2303/19 concerning a vaccine composition (Board of Appeal)
  • Appeal T1977/21 concerning attenuated viruses (Board of Appeal)
  • Appeal T0489/20 concerning a transdermal system for treating pain (Board of Appeal)
  • 2 BvR 561/18, 2 BvR 756/16, 2 BvR 786/15 regarding the independence of the Boards of Appeal (German Constitutional Court)
  • R 02/15, R 05/15, R 08/13 regarding the independence of members of the Boards of Appeal and the right to be heard (Enlarged Board of Appeal)
  • T1938/09 regarding a transdermal system for treating pain (Board of Appeal)
  • 315 O 383/17 regarding a transdermal system for treating pain (District Court of Hamburg)
  • 21 O 6972/16, 4c O 20/16 regarding a transdermal system for treating pain (district court of Munich)
  • T0259/15 regarding a transdermal system for treating pain (Board of Appeal)
  • T1676/08 regarding an oral controlled release pain medicament (Board of Appeal)

  • German Patent Attorney Association
  • AIPPI
  • epi
  • FICPI
  • GRUR

  • German
  • English